Norway, Nov. 4 -- Zelluna, a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Research Council of Norway has approved a grant of NOK 15.6 million to Zelluna under the Innovation Project for the Industrial Sector (IPN) scheme. * NOK 15.6 million non-dilutive grant awarded by the Research Council of Norway * Funding will enable further manufacturing development, strengthen the cost-of-goods advantage of Zelluna's off-the-shelf TCR-NK platform and support * Zelluna's strategy to make TCR-NK cell therapies broadly accessible to patients with solid cancers * Award subject to final contract negotiations with the Research Council ...